⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Andrographis eases ankylosing spondylitis and psoriasis. This page keeps it as a report of what people, websites or other media say.
Andrographis Anti-Inflammatory Effects
Andrographolide is one of the most potent natural-product inhibitors of NF-kB (nuclear factor kappa-B) signaling identified to date. The mechanism is unusually elegant: the alpha,beta-unsaturated lactone functional group of andrographolide forms a covalent bond with cysteine 62 of the NF-kB p50 subunit (demonstrated definitively by Xia and colleagues in 2004), blocking the p50/p65 heterodimer from binding kappa-B promoter elements in DNA. The downstream consequence is sweeping suppression of NF-kB-driven gene expression: tumor necrosis factor-alpha, interleukin-1-beta, interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), iNOS, ICAM-1, VCAM-1, E-selectin, and dozens of other inflammatory mediators are downregulated simultaneously. This single-target/multi-effect profile is the proposed reason a single botanical has been studied across rheumatoid arthritis (Burgos 2009 trial), osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, and acute lung injury models — all of which are downstream of NF-kB-driven cytokine cascades. This deep-dive walks through the molecular mechanism, the clinical trial evidence in each indication, and the cautions and drug-interaction findings.
Table of Contents
- NF-kB as the Master Regulator of Inflammation
- Cysteine-62 Covalent Inhibition (Xia 2004)
- Downstream Cytokine Suppression (Tumor Necrosis Factor, Interleukin-1, Interleukin-6)
- Cyclooxygenase-2 and iNOS Downregulation
- ICAM-1 / VCAM-1 Endothelial Adhesion Suppression
- Rheumatoid Arthritis: The Burgos 2009 Trial
- Osteoarthritis
- Ankylosing Spondylitis and Psoriasis
- Ulcerative Colitis Trials
- Acute Lung Injury and Cytokine Storm Models
- PEPT1 / PEPT2 Transporter Interaction Is Not Established
- Comparison with Nonsteroidal Anti-Inflammatory Drugs and Biologic Anti-TNF Therapy
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
NF-kB as the Master Regulator of Inflammation
NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is the transcription factor system that orchestrates the cellular response to inflammatory and stress signals across essentially all cell types in the body. Activation of NF-kB downstream of tumor necrosis factor-alpha, IL-1, TLR agonists (lipopolysaccharide (LPS), viral RNA, bacterial DNA), reactive oxygen species, or DNA damage produces a coordinated transcriptional response — upregulation of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1-beta, interleukin-6, IL-8), prostaglandin/leukotriene synthesizing enzymes (cyclooxygenase-2, iNOS), endothelial adhesion molecules (ICAM-1, VCAM-1, E-selectin), antiapoptotic proteins (Bcl-xL, c-FLIP, cIAP1/2), and matrix metalloproteinases (MMP-1, MMP-3, MMP-9).
The architecture: NF-kB is a family of dimeric transcription factors built from five subunits (p50, p52, p65/RelA, RelB, c-Rel). The most common active form is the p50/p65 heterodimer. In resting cells, the dimer is held in the cytoplasm bound to the inhibitor protein I-kB-alpha. Upon activation, the upstream IkB kinase (IKK) complex phosphorylates I-kB-alpha, targeting it for ubiquitination and proteasomal degradation, which releases the p50/p65 heterodimer to translocate to the nucleus where it binds kappa-B promoter elements and activates transcription.
The therapeutic problem with NF-kB as a target: it is essential for normal immune defense, normal lymphoid development, and normal cellular stress response. Complete blockade is incompatible with life. The successful pharmaceutical anti-inflammatory strategy has therefore been to target downstream effectors (anti-TNF biologics, anti-IL-1 biologics, anti-IL-6 biologics, JAK inhibitors) rather than NF-kB itself.
Andrographolide is unusual in producing partial, selective NF-kB inhibition that reduces the inflammatory transcriptional program without abolishing it. The cysteine-62 mechanism is selective enough to spare some NF-kB functions while clearly attenuating others, producing measurable clinical benefit in autoimmune indications with tolerability that is closer to nonsteroidal anti-inflammatory drugs (NSAIDs) than to biologics or corticosteroids.
Cysteine-62 Covalent Inhibition (Xia 2004)
The molecular basis for andrographolide's NF-kB inhibition was described by Xia and colleagues in a 2004 Journal of Immunology paper. While screening a library of traditional Chinese herbal medicine extracts, they found that andrographolide strongly inhibited NF-kB activity, and reported:
- Andrographolide forms a covalent adduct specifically with the reduced cysteine-62 residue of the NF-kB p50 subunit, via Michael addition of the cysteine thiol to the alpha,beta-unsaturated lactone of andrographolide
- This covalent modification blocks NF-kB from binding its DNA sequence, preventing transcription of downstream target genes
- It works at that last step only: andrographolide had no suppressive effect on the breakdown of the inhibitor protein I-kB-alpha, on the movement of p50 and p65 into the nucleus, or on cell growth rates
- In stimulated endothelial (blood-vessel lining) cells, it lowered the adhesion molecule E-selectin and prevented E-selectin-mediated white-cell adhesion under flow
- In animals, it blocked the build-up of neutrophils in the abdominal cavity triggered by cytokines and endotoxin, attenuated septic shock, and prevented allergic lung inflammation; these in-vivo results are animal findings, not human ones
The cysteine-62 mechanism places andrographolide in a small class of natural-product covalent NF-kB inhibitors that includes parthenolide (from feverfew), helenalin (from arnica), and several sesquiterpene lactones from the daisy family. The "Michael acceptor" alpha,beta-unsaturated carbonyl functional group is the common chemical handle that allows these molecules to covalently modify cysteine thiols on regulatory proteins.
A practical consequence: because the inhibition is covalent, the duration of effect outlasts the plasma half-life of andrographolide itself. New synthesis of unmodified p50 subunit is required to restore full NF-kB activity, which takes hours rather than the minutes that would be characteristic of a non-covalent reversible inhibitor. This is part of why a thrice-daily dosing schedule (rather than continuous intravenous (IV) infusion) is clinically sufficient.
Downstream Cytokine Suppression (Tumor Necrosis Factor, Interleukin-1, Interleukin-6)
The single most clinically impactful consequence of NF-kB inhibition is reduced transcription of the inflammatory cytokine triumvirate that drives most chronic inflammatory disease:
- Tumor necrosis factor-alpha — the master inflammatory cytokine, central to rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis. The targets of infliximab, adalimumab, etanercept, golimumab, certolizumab.
- Interleukin-1-beta — the cytokine of acute inflammation, central to gout, autoinflammatory syndromes (familial Mediterranean fever, cryopyrin-associated periodic syndromes), and atherosclerosis. The target of anakinra and canakinumab.
- Interleukin-6 (IL-6) — the cytokine of chronic inflammation and acute-phase response, central to rheumatoid arthritis, giant cell arteritis, Castleman's disease, and cytokine release syndrome from CAR-T therapy. The target of tocilizumab and sarilumab.
Andrographolide simultaneously reduces transcription of all three cytokines through the upstream NF-kB inhibition. In cell-culture studies of lipopolysaccharide-stimulated macrophages, andrographolide at 5-30 micromolar concentrations reduces tumor necrosis factor-alpha production by 50-80%, interleukin-1-beta production by 40-70%, and interleukin-6 production by 40-70%. The effect is dose-dependent and reproducible across multiple macrophage cell lines and primary macrophage cultures.
In animal models of acute inflammation (lipopolysaccharide-induced endotoxemia, collagen-induced arthritis, dextran-sulfate-induced colitis), oral andrographolide administration produces measurable reduction in serum cytokine levels and corresponding reduction in clinical disease severity scores. The effect is generally smaller than that of biologic anti-cytokine therapy but is achieved with an oral small-molecule botanical at a tiny fraction of the cost.
Cyclooxygenase-2 and iNOS Downregulation
Beyond cytokines, NF-kB activation drives transcription of two other inflammation-amplifying enzymes:
- cyclooxygenase-2 (COX-2) — the inducible isoform of cyclooxygenase that generates prostaglandin E2 and prostaglandin I2 from arachidonic acid at sites of inflammation. The principal target of nonsteroidal anti-inflammatory drugs and the more selective coxib drugs (celecoxib, etoricoxib).
- iNOS (inducible nitric oxide synthase, NOS2) — generates large quantities of nitric oxide from arginine in activated macrophages and other inflammatory cells. The high-output nitric oxide reacts with superoxide to form peroxynitrite, a major mediator of inflammatory tissue damage and oxidative stress.
Andrographolide downregulates both cyclooxygenase-2 and iNOS transcription via NF-kB inhibition. The cyclooxygenase-2 effect produces a mild prostaglandin-reducing anti-inflammatory effect comparable to (but smaller than) ibuprofen or naproxen, with the advantage of being achieved without the cyclooxygenase-1 (COX-1) inhibition that drives the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. The iNOS effect reduces inflammatory nitric oxide production without affecting the constitutive endothelial NOS (eNOS) that maintains normal vasodilator tone and blood pressure regulation.
The result is a botanical with a mechanism of action that overlaps with nonsteroidal anti-inflammatory drugs (via cyclooxygenase-2 downregulation) and with the experimental iNOS inhibitor drug class (which has so far failed to produce a viable pharmaceutical), but without the gastrointestinal (GI) bleeding risk of nonsteroidal anti-inflammatory drugs and without the cardiovascular hypertension risk of pharmaceutical iNOS inhibition.
ICAM-1 / VCAM-1 Endothelial Adhesion Suppression
Leukocyte recruitment from circulation into inflamed tissue requires a coordinated sequence of capture, rolling, firm adhesion, and transmigration across the endothelium. Each step depends on specific adhesion molecules:
- E-selectin and P-selectin — endothelial proteins that mediate initial capture and rolling of leukocytes
- ICAM-1 (intercellular adhesion molecule-1) — mediates firm adhesion of leukocytes to endothelium via leukocyte LFA-1 and Mac-1 integrins
- VCAM-1 (vascular cell adhesion molecule-1) — preferentially recruits monocytes and lymphocytes via VLA-4 integrin, important in chronic inflammation and atherosclerosis
NF-kB drives transcription of all three. Andrographolide inhibition of NF-kB downregulates ICAM-1, VCAM-1, and E-selectin expression on activated endothelium, with the functional consequence of reduced leukocyte recruitment into inflamed tissue. This is an upstream mechanism for reducing inflammatory cell infiltration, complementary to (and in many ways more proximal than) cytokine suppression.
The endothelial adhesion suppression is relevant to chronic vascular inflammation (atherosclerosis), to inflammatory bowel disease (where the integrin antagonist vedolizumab and the anti-MAdCAM-1 antibodies exploit the same biology pharmaceutically), and to autoimmune disease in general where leukocyte recruitment into target tissue is the rate-limiting step in chronic disease progression.
Rheumatoid Arthritis: The Burgos 2009 Trial
The main clinical trial for Andrographis in rheumatoid arthritis (RA) is Burgos and colleagues 2009, published in Clinical Rheumatology. In this prospective, randomized, double-blind, placebo-controlled trial, 60 patients with active rheumatoid arthritis took tablets made of an Andrographis paniculata extract (30% total andrographolides) or placebo three times a day for 14 weeks, after a 2-week washout period.
What the trial found:
- The primary outcome was joint pain intensity on a visual analog pain scale. Pain decreased in the active group compared with placebo at the end of treatment, but the difference was not statistically significant.
- Within the group taking the extract, the number of tender joints, the number of swollen joints, the total grades of tender and swollen joints, and two health questionnaires (HAQ and SF36) improved significantly week by week. These are changes inside one group, not differences from placebo.
- The extract was associated with a reduction of rheumatoid factor, immunoglobulin A (IgA) and complement C4.
The authors wrote that Andrographis paniculata “could be a useful ‘natural complement’” in rheumatoid arthritis treatment, but that “a larger trial and a more extended period of treatment is necessary” to confirm the results.
What is not known: no larger or longer placebo-controlled trial of Andrographis in rheumatoid arthritis was found in PubMed, so a benefit on pain or joint counts beyond placebo has not been shown.
See our Arthritis page for the broader context of rheumatoid arthritis management.
Osteoarthritis
Osteoarthritis (OA) is mechanistically distinct from rheumatoid arthritis — primarily a non-autoimmune disease of cartilage breakdown driven by mechanical wear, age, obesity, and prior joint injury. However, there is now ample evidence that chronic low-grade inflammation in the synovial membrane (synovitis) is a substantial contributor to OA pain and to ongoing cartilage damage. The same NF-kB-driven inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1-beta, interleukin-6) are upregulated in OA synovium and contribute to chondrocyte production of cartilage-degrading matrix metalloproteinases.
One randomized, double-blind, placebo-controlled trial of Andrographis in osteoarthritis was found in PubMed. It enrolled 103 men and women with grade I–II knee osteoarthritis, who took a standardized Andrographis paniculata extract at 300 or 600 mg per day (total daily dose) or placebo. Both doses reduced WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain compared with placebo at days 28, 56 and 84. Stiffness, physical function and fatigue scores also improved significantly in both extract groups compared with placebo, and at the end of the study quality-of-life (SF-36) and FACIT (Functional Assessment of Chronic Illness Therapy) scores were better in both extract groups. The authors concluded that both doses were effective and safe in mild to moderate knee osteoarthritis.
What is not known: the trial had no nonsteroidal anti-inflammatory drug (NSAID) comparison group and no hand-osteoarthritis arm, and no trial comparing Andrographis with the established osteoarthritis treatments (weight loss, structured exercise, physical therapy, topical or oral NSAIDs, intra-articular hyaluronate or steroid injection) was found.
Curcumin (turmeric) and Boswellia serrata extract act through other anti-inflammatory pathways (curcumin inhibits NF-kB via a different mechanism, Boswellia inhibits 5-lipoxygenase, reducing leukotriene production); no trial of Andrographis combined with them in arthritis was found.
Ankylosing Spondylitis and Psoriasis
Ankylosing spondylitis (AS) and psoriasis (and their related conditions psoriatic arthritis and other spondyloarthritides) are linked by their dependence on the IL-23 / IL-17 / Th17 axis. The pharmaceutical drug class that targets this axis (IL-17 antagonists secukinumab, ixekizumab; IL-23 antagonists guselkumab, risankizumab, tildrakizumab) has been transformative for these conditions over the past decade.
Andrographolide's NF-kB inhibition reduces interleukin-6 and tumor necrosis factor-alpha production by activated dendritic cells and Th17 cells, with downstream effects on Th17 differentiation and IL-17 production. The mechanism is mechanistically aligned with the IL-23/IL-17 axis biology even if andrographolide is not directly targeting the cytokines themselves.
No human trial of Andrographis in ankylosing spondylitis or psoriasis was found in PubMed; the published work found is laboratory, mouse and computer-modelling research. Andrographis is promoted as an adjunct in ankylosing spondylitis and psoriasis for people taking conventional disease-modifying antirheumatic drugs (DMARDs), such as sulfasalazine and methotrexate, who are seeking additional symptom control short of escalating to biologics, or as part of a wider anti-inflammatory diet and supplement program; this use rests on the mechanism above, not on human trial results.
Ulcerative Colitis Trials
In a randomized, double-blind, placebo-controlled trial published in 2013, 224 adults with mild-to-moderate ulcerative colitis took an Andrographis paniculata extract at 1,200 mg or 1,800 mg daily, or placebo, for 8 weeks. At week 8, 60% of patients on 1,800 mg daily were in clinical response compared with 40% on placebo (P=0.0183); the 1,200 mg dose (45% in response) did not differ significantly from placebo (P=0.5924). Clinical remission rates (34% and 38%, against 25% on placebo) were not significantly different. Adverse events developed in 60% and 53% of patients in the two extract groups and in 60% of the placebo group.
A 2024 systematic review and meta-analysis of 28 randomized trials covering 18 herbs in active ulcerative colitis found that, pooled against placebo, Andrographis paniculata did not significantly raise clinical response (risk ratio 0.95, 95% confidence interval 0.71–1.26) or clinical remission (risk ratio 1.31, 95% confidence interval 0.86–2.01). In the same analysis, Indigo naturalis raised clinical response and Curcuma longa (turmeric) raised clinical remission compared with placebo.
Acute Lung Injury and Cytokine Storm Models
Acute lung injury (ALI) and its severe form acute respiratory distress syndrome (ARDS) are driven by overwhelming pulmonary inflammation in response to triggers including sepsis, severe viral pneumonia (influenza, respiratory syncytial virus (RSV), historical SARS), aspiration, and major trauma. The pathophysiology centers on alveolar macrophage tumor necrosis factor-alpha and interleukin-6 release driving neutrophil recruitment, capillary leak, surfactant inactivation, and ultimately diffuse alveolar damage.
Multiple animal-model studies document that andrographolide administration substantially attenuates lipopolysaccharide-induced and influenza-induced acute lung injury through the predictable NF-kB-mediated reduction in tumor necrosis factor-alpha, interleukin-6, and neutrophil recruitment. The Bao 2009 paper in the American Journal of Respiratory and Critical Care Medicine established andrographolide as a candidate molecule for further drug development in airway inflammatory disease, with detailed mechanistic work in ovalbumin-induced asthma models.
It is important to be clear about scope: animal-model evidence does not translate directly to human ARDS management, and Andrographis is not a substitute for the established ARDS interventions (lung-protective ventilation, prone positioning, fluid management, treatment of the underlying trigger). The acute lung injury mechanism is, however, mechanistically illuminating about why Andrographis produces broad reduction in symptom severity in viral upper respiratory tract infection — the lung-injury cytokine cascade is a smaller, less severe version of the same biology playing out in uncomplicated influenza and the common cold.
PEPT1 / PEPT2 Transporter Interaction Is Not Established
The oligopeptide transporters PEPT1 (intestinal, SLC15A1) and PEPT2 (renal proximal tubule, SLC15A2) normally absorb small di- and tri-peptides from the gut lumen and reabsorb filtered peptides in the kidney. They also serve as the absorption mechanism for several pharmaceutical drugs designed as peptide mimetics, including the beta-lactam antibiotics (cefadroxil, amoxicillin), the angiotensin-converting enzyme inhibitor (ACE inhibitor) enalapril, the antiviral valacyclovir, and the experimental dipeptide JBP485 (Cyclo-trans-4-L-hydroxyprolyl-L-serine).
An interaction between andrographolide and these transporters is not established. PubMed searches for andrographolide with PEPT1, with JBP485 or with valacyclovir returned no studies, and none of the published JBP485 studies found involves Andrographis.
Comparison with Nonsteroidal Anti-Inflammatory Drugs and Biologic Anti-TNF Therapy
Where does Andrographis fit in the anti-inflammatory therapeutic landscape?
| Agent | Mechanism | Effect Size | Key Toxicity |
|---|---|---|---|
| Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) | Cyclooxygenase-1 / cyclooxygenase-2 inhibition | Moderate symptomatic | Gastrointestinal bleeding, renal injury, cardiovascular risk |
| Coxibs (celecoxib) | Selective cyclooxygenase-2 inhibition | Moderate symptomatic | Cardiovascular risk, renal injury |
| Corticosteroids | Broad transcriptional anti-inflammatory | Large symptomatic, no disease modification | Diabetes, osteoporosis, infection, weight gain |
| Methotrexate | Folate antagonist, multiple downstream | Disease-modifying in rheumatoid arthritis | Liver, lung, bone marrow, gastrointestinal |
| Anti-TNF biologics (infliximab) | Direct tumor necrosis factor-alpha neutralization | Large, disease-modifying | Infection (tuberculosis, hepatitis B virus), demyelination, lupus, cost |
| Andrographis | NF-kB p50 covalent inhibition | Mild-to-moderate symptomatic | Mild (taste, gastrointestinal, rare allergic rash); pregnancy contraindication |
On the evidence above, Andrographis is positioned as an adjunct, not a replacement, for established DMARDs and biologics in moderate-to-severe autoimmune disease. Its proposed uses are in mild disease where conventional DMARDs would be over-treatment, alongside existing DMARDs for people with persistent symptoms, as a partial alternative to nonsteroidal anti-inflammatory drugs for people who cannot tolerate them, and as a long-term anti-inflammatory adjunct for people seeking to reduce cumulative anti-inflammatory drug burden.
Cautions and Drug Interactions
- Pregnancy — absolute contraindication. Uterine stimulant. Reiterated on every Andrographis page.
- Anticoagulants and antiplatelets — in the one warfarin interaction study found, rats given an Andrographis paniculata and Eleutherococcus senticosus combination extract for 5 days, at an andrographolide dose some 17-fold higher than that recommended for humans, showed no significant change in the pharmacokinetics of warfarin and practically no effect on its pharmacodynamics (prothrombin time). No study of Andrographis with dabigatran, apixaban, rivaroxaban, aspirin or clopidogrel was found, so its effect on bleeding with these drugs in people is not known.
- Immunosuppressants for organ transplant or biologic anti-TNF therapy — no interaction study of Andrographis with organ-transplant immunosuppressants such as tacrolimus or cyclosporine was found; because Andrographis also dampens immune signalling through NF-kB, its effect on top of these drugs is not known. The rheumatology uses on this page describe it alongside low-dose conventional DMARDs (methotrexate, sulfasalazine).
- Pharmaceutical nonsteroidal anti-inflammatory drugs — the mechanisms are partially overlapping (both produce cyclooxygenase-2 downregulation, but Andrographis works upstream via NF-kB inhibition while nonsteroidal anti-inflammatory drugs work directly on the COX enzymes). Gastrointestinal side effects can add up when both are taken.
- Antihypertensives — Andrographis modestly reduces blood pressure, which can add to the effect of blood-pressure medicines.
- Antidiabetics — Andrographis has mild glucose-lowering activity, which can add to the effect of diabetes medicines.
- Bitter taste and gastrointestinal upset — standard tolerability issues; capsules, food, divided dosing.
- Allergic skin rash — rare but documented.
- Headache — uncommon, usually mild and transient.
- Pediatric use in autoimmune disease — safety in children is not well established.
Key Research Papers
- Xia YF, Ye BQ, Li YD, et al. (2004). Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. Journal of Immunology. — PubMed PMID: 15356172
- Burgos RA, Hancke JL, Bertoglio JC, et al. (2009). Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clinical Rheumatology. — PubMed PMID: 19408036
- Hancke JL, Srivastav S, Cáceres DD, Burgos RA (2019). A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. Phytotherapy Research. — PubMed PMID: 30968986
- Sandborn WJ, Targan SR, Byers VS, et al. (2013). Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. American Journal of Gastroenterology. — PubMed PMID: 23044768
- Iyengar P, Godoy-Brewer G, Maniyar I, et al. (2024). Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Nutrients. — PubMed PMID: 38612967
- Hovhannisyan AS, Abrahamyan H, Gabrielyan ES, Panossian AG (2006). The effect of Kan Jang extract on the pharmacokinetics and pharmacodynamics of warfarin in rats. Phytomedicine. — PubMed PMID: 16635739
- Bao Z, Guan S, Cheng C, et al. (2009). A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. American Journal of Respiratory and Critical Care Medicine. — PubMed PMID: 19201922
- Wang T, Liu B, Zhang W, et al. (2004). Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. Journal of Pharmacology and Experimental Therapeutics. — PubMed PMID: 14718612
- Hidalgo MA, Romero A, Figueroa J, et al. (2005). Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. British Journal of Pharmacology. — PubMed PMID: 15678086
- Liu J, Wang ZT, Ji LL (2007). In vivo and in vitro anti-inflammatory activities of neoandrographolide. American Journal of Chinese Medicine. — PubMed PMID: 17436371
- Chao WW, Lin BF (2010). Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chinese Medicine. — PubMed PMID: 20465823
- Chandrasekaran CV, Thiyagarajan P, Sundarajan K, et al. (2009). Evaluation of the genotoxic potential and acute oral toxicity of standardized extract of Andrographis paniculata (KalmCold). Food and Chemical Toxicology. — PubMed PMID: 19447157
- Lee KC, Chang HH, Chung YH, Lee TY (2011). Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-kappaB pathway. Journal of Ethnopharmacology. — PubMed PMID: 21497192
- Akbar S (2011). Andrographis paniculata: a review of pharmacological activities and clinical effects. Alternative Medicine Review. — PubMed PMID: 21438648